Zinzani, P. L. L. Et Al. 2023. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.. Blood .

Zinzani, P. L. L., Thieblemont, C., Melnichenko, V., Bouabdallah, K., Walewski, J., Majlis, A., ... Fogliatto, L. M.(2023). Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.. Blood .

Zinzani, Pier Et Al. "Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.," Blood , 2023

Zinzani, Pier L. Et Al. "Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.." Blood , 2023

Zinzani, P. L. L. Et Al. (2023) . "Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.." Blood .

@article{article, author={Pier Luigi Luigi Zinzani Et Al. }, title={Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170.}, journal={Blood}, year=2023}